Evidence map›Paper›PMID 34938274›Full record

ArticleFrontiers in endocrinology2021

Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society.

Tereza Planck, Mikael Lantz, Petros Perros, Enrico Papini, Roberto Attanasio, Endre V Nagy, Laszlo Hegedüs

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Mechanism Study on Chinese Medicine in Treatment of Nodular Goiter.Chinese journal of integrative medicine · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?International journal of endocrinology and metabolism · 2022
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 5 countries.

Tereza PlanckDepartment of Endocrinology, Skåne University Hospital, Malmö, Sweden.
Mikael LantzDepartment of Endocrinology, Skåne University Hospital, Malmö, Sweden.
Petros PerrosDepartment of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
Enrico PapiniDepartment of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.
Roberto AttanasioEndocrine Unit, Institutes for Care and Scientific Research (IRCCS) Orthopedic Institute Galeazzi, Milan, Italy.
Endre V NagyDivision of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Laszlo HegedüsDepartment of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.
Istituti di Ricovero e Cura a Carattere Scientifico · ITLund University · SEOdense University Hospital · DKOspedale Regina Apostolorum · ITRoyal Victoria Infirmary · GBSkåne University Hospital · SEUniversity of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The standard treatment of hypothyroidism is levothyroxine (LT-4). However, there are several controversies regarding treatment of hypothyroid patients. Aim: To investigate the Swedish endocrinologists' use of thyroid hormones in hypothyroid and euthyroid individuals. Methods: Physician members of the Swedish Endocrine Society (SEF) were invited by e-mail to participate in an online survey investigating this topic. Results: Out of the eligible 411 members, 116 (28.2%) responded. The majority (98.9%) stated that L-T4 is the treatment of choice. However, around 50% also prescribed liothyronine (L-T3) or a combination of L-T4+L-T3 in their practice. Combination therapy was mostly (78.5%) used in patients with persistent hypothyroid symptoms despite biochemical euthyroidism on L-T4 treatment. Most respondents prescribed L-T4 tablets and did not expect any major changes with alternative formulations such as soft-gel capsules or liquid formulations in situations influencing the bioavailability of L-T4. In euthyroid patients, 49.5% replied that treatment with thyroid hormones was never indicated, while 47.3% would consider L-T4 for euthyroid infertile women with high thyroid peroxidase (TPO) antibody levels. Conclusion: The treatment of choice for hypothyroidism in Sweden is L-T4 tablets. Combination therapy with L-T4+L-T3 tablets was considered for patients with persistent symptoms despite biochemical euthyroidism. Soft-gel capsules and liquid solutions of L-T4 were infrequently prescribed. Swedish endocrinologists' deviation from endocrine society guidelines merits further study.

Indexed as

Surveys and QuestionnairesAdultAgedDrug Therapy, CombinationFemaleGoiter, NodularHumansHypothyroidismMaleMiddle AgedPhysiciansSocieties, MedicalSwedenThyroid HormonesThyroxineTriiodothyronineThyroid HormonesThyroxineTriiodothyroninedesiccated thyroid extract (DTE)euthyroidismhypothyroidismlevothyroxineliothyroninesurveySwedish Endocrine Society

Identifiers

PMID34938274
PMCPMC8687360
OpenAlexW4200498494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.